Please Wait a Moment
X

Articles

04Jan

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

04 Jan, 2022 | Return|

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 convalescent plasma.  The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment.  Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.

We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines. 

 

 

 

Related

Upcoming HCV Testing Algorithm Change

FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...

Read More >

CTS Form Updates 2020

CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...

Read More >

Reminder-Check flights and cargo hours for the Labor Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

Exhibiting at AABB Annual Meeting- Booth 732

We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...

Read More >

FDA Guidance ZIKV Testing Strategy Webinar

On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...

Read More >

FDA Guidance for Industry for Babesia

On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...

Read More >